Drug intelligence / Profile preview

bezacitinib

Development stage: Unknown
Lead developer: Hangzhou Bangshun Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Bezacitinib (OB756) is an orally bioavailable small molecule Janus kinase (JAK) inhibitor developed by Hangzhou Bangshun Pharmaceutical. It is currently in Phase 1 clinical development, specifically being evaluated for the treatment of type 1 diabetes mellitus. The drug is designed to modulate immune signaling pathways that contribute to the autoimmune destruction of pancreatic beta cells. Clinical trials in healthy participants have been initiated to characterize its safety, tolerability, pharmacokinetics, and pharmacodynamics, including relative bioavailability when administered as a tablet formulation.

Other names: bezacitinib

Targets

JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on bezacitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bezacitinib.

Explore the full profile